Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
Table 3
Hemodynamic changes during treatment.
Parameters
All ()
Responders ()
Nonresponders ()
value
Maximum HR—1/min
At baseline
127 (70–163)
128 (75–160)
115 (70–163)
0.39
After 10 minutes
112 (60–146)
111 (70–140)
113 (60–146)
0.55
After 30 minutes
105 (61–155)
92 (64–146)
110 (61–155)
0.43
After 60 minutes
99 (69–139)
89 (70–130)
110 (69–139)
0.47
After 120 minutes
95 (70–158)
89 (70–146)
107 (74–158)
0.26
NA requirements
At baseline
11 (34%)
6 (35%)
5 (33%)
1.00
Dose—mcg/kg/min
0.00 (0.00–0.10)
0.00 (0.00–0.05)
0.00 (0.00–0.10)
0.82
MAP
At baseline
67 (54–90)
65 (54–86)
68 (62–90)
0.11
After 10 minutes
73 (57–103)
72 (57–92)
75 (62–103)
0.58
After 30 minutes
77 (55–103)
72 (55–88)
84 (59–103)
0.02
After 60 minutes
70 (54–101)
70 (54–101)
75 (55–96)
0.19
After 120 minutes
72 (60–106)
71 (60–85)
76 (62–106)
0.04
Lactate—mmol/L
At baseline
1.1 (0.6–2.1)
1.0 (0.6–2.1)
1.1 (0.8–1.6)
0.92
After 120 minutes
1.2 (0.6–3.1)
1.1 (0.6–3.1)
1.3 (0.9–1.5)
0.79
SvO2—%
At baseline
63 (49–75)
64 (51–75)
60 (49–75)
0.22
After 120 minutes
65 (48–75)
63 (48–75)
65 (55–72)
0.75
HR: heart rate; MAP: mean arterial pressure; NA: noradrenaline. Results are given as median (minimum–maximum) or numbers (percentages). Groups were compared with Fisher’s exact test or the Mann-Whitney test, as appropriate.
